FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
18/06/2026
Voltar para busca
Dado oficial do USPTO
INVIOS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
INVIOS
ST13
US500000079355607Classe
1, 5, 10, 42
Pedido
79355607
Registro
8026380
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
34
Atualização mais recente
19/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 10, 42
Data de depósito
21/06/2022
Data de registro
18/11/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
18/11/2025
Última transação
19/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
16
Localização do titular
AT
Examinador
CLYBURN, CARLA DIONNE
Unidade examinadora
M10
Localização atual
PETITIONS OFFICE
Titulares e representantes
Titulares
invIOs GmbH
Representantes
Michael J. Leonard Fox Rothschild LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 10Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemical, biochemical and biotechnological preparations used in industry and science
Classe 5
Pharmaceutical and veterinary pharmaceutical preparations and substances for treatment of cancer, regulating the immune system, treatment of immune system diseases and disorders, and for cell therapy; diagnostic preparations for medical purposes in the nature of treatment of cancer, regulating the immune system, treatment of immune system diseases and disorders, and for cell therapy; biopharmaceutical, biological and chemical preparations and substances for medical use in the nature of treatment of cancer, regulating the immune system, treatment of immune system diseases and disorders, and for cell therapy; pharmaceutical and veterinary pharmaceutical preparations and substances for the treatment of cancer, regulation of the immune system, treatment of diseases of the immune system and cell therapy
Classe 10
Surgical and veterinary apparatus and instruments for the treatment and prevention of cancer, for the regulation of the immune system, for the treatment of diseases of the immune system, for cell therapy; medical diagnostic apparatus for testing blood cells, cancer cells and immune cells as therapeutic agents and modifications thereof; medical apparatus and instruments for the treatment and prevention of cancer, for the regulation of the immune system, for the treatment of diseases of the immune system, for cell therapy; medical apparatus and instruments for preparing and processing blood and other cell preparations for medical purposes in the nature of cancer treatment, regulation of the immune system and treatment of diseases of the immune system and cell therapy; medical apparatus and instruments for cell therapy; parts for the aforesaid goods, included in this class and only for purposes before mentioned
Classe 42
Surgical and veterinary apparatus and instruments for the treatment and prevention of cancer, for the regulation of the immune system, for the treatment of diseases of the immune system, for cell therapy; medical diagnostic apparatus for testing blood cells, cancer cells and immune cells as therapeutic agents and modifications thereof; medical apparatus and instruments for the treatment and prevention of cancer, for the regulation of the immune system, for the treatment of diseases of the immune system, for cell therapy; medical apparatus and instruments for preparing and processing blood and other cell preparations for medical purposes in the nature of cancer treatment, regulation of the immune system and treatment of diseases of the immune system and cell therapy; medical apparatus and instruments for cell therapy; parts for the aforesaid goods, included in this class and only for purposes before mentioned.
Publicações
Histórico de despachos e eventos da marca no USPTO.
34 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
30/05/2026
FIMP
FINAL DISPOSITION PROCESSED
30/05/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
18/02/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
18/11/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
18/11/2025
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
19/05/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
07/05/2024
CHPB
POST PUBLICATION AMENDMENT - ENTERED
22/04/2024
APET
ASSIGNED TO PETITION STAFF
22/04/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
17/04/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
17/04/2024
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
13/03/2024
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
05/02/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/01/2024
PUBO
PUBLISHED FOR OPPOSITION
09/01/2024
GPNX
NOTIFICATION PROCESSED BY IB
08/01/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
20/12/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
20/12/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
20/12/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
29/11/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
29/11/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/11/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
28/11/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/11/2023
RFNT
REFUSAL PROCESSED BY IB
26/06/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/06/2023
RFRR
REFUSAL PROCESSED BY MPU
05/06/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/04/2023
CNRT
NON-FINAL ACTION WRITTEN
06/04/2023
DOCK
ASSIGNED TO EXAMINER
31/03/2023
MAFR
APPLICATION FILING RECEIPT MAILED
22/11/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
18/11/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
17/11/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace INVIOS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.